Growth opportunity ReShape Lifesciences is expanding its weight loss portfolio with both surgical and non-surgical solutions, including the Lap-Band program and the ReShape Care virtual management program, signaling multiple cross-sell and upsell opportunities with physicians, clinics, and payors in obesity treatment.

Strategic partnerships Recent partnerships and distribution agreements (e.g., Recon Supply) indicate a channel expansion strategy that can be leveraged to accelerate market penetration, create co-selling motions with distributors, and broaden availability of the Lap-Band and related programs in the U.S. market.

Clinical progression The ReShape Vest is in European clinical trials and not yet commercially available, presenting a potential future product launch opportunity for early adopters, clinical trial partnerships, and pilot programs to establish efficacy data and payer acceptance.

Innovative tech Development initiatives such as the Diabetes Bloc-Stim Neuromodulation system and AI-driven neurorehabilitation collaborations expand the company’s tech footprint, offering potential cross-sell to neurologic, metabolic, and obesity care pathways and expanded device portfolios for integrated care.

Market readiness With revenue in the low to mid single digits and substantial funding backing, there is capacity for scaled sales efforts, targeted outreach to healthcare providers and clinics, and compelling ROI narratives for payors focused on durable weight management and obesity-related comorbidity reduction.